150 related articles for article (PubMed ID: 38259447)
1. Disease patterns and specific trajectories of anti-MDA5-related disease: a multicentre retrospective study of 70 adult patients.
de Boysson H; Cuchet M; Cassius C; Cuchet P; Agard C; Audemard-Verger A; Marchand-Adam S; Cohen-Sors R; Gallay L; Graveleau J; Lesort C; Ly K; Meyer A; Monseau G; Néel A; Bonnotte B; Pérard L; Schleinitz N; Mariotte D; Le Mauff B; Bourdenet G; Masmoudi W; Deshayes S; Dumont A; Dompmartin A; Kottler D; Aouba A
Front Immunol; 2023; 14():1319957. PubMed ID: 38259447
[TBL] [Abstract][Full Text] [Related]
2. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
[TBL] [Abstract][Full Text] [Related]
3. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
Li M; Zhao X; Liu B; Zhao Y; Li X; Ma Z; Yang Q
Front Immunol; 2023; 14():1209282. PubMed ID: 37691917
[TBL] [Abstract][Full Text] [Related]
4. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
[No Abstract] [Full Text] [Related]
8. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
11. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
12. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
Ji Q; Pan W; Zhang D; Hou Y; Wang Z
Front Immunol; 2023; 14():1237209. PubMed ID: 38098481
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease in Chinese patients.
Lian L; Tong JJ; Xu SQ
Immun Inflamm Dis; 2023 Jun; 11(6):e882. PubMed ID: 37382274
[TBL] [Abstract][Full Text] [Related]
14. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].
Zhang PL; Yang HX; Zhang LN; Ge YP; Peng QL; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1055-1060. PubMed ID: 34916681
[TBL] [Abstract][Full Text] [Related]
15. Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies.
Ramos-Martinez E; Rodríguez-Vega EA; Rivera-Matias PA; Falfán-Valencia R; Pérez-Rubio G; Mejia M; González-Pérez MI; Buendia-Roldán I; Mateos-Toledo HN; Serrano JR
Med Clin (Barc); 2023 Dec; 161(12):515-522. PubMed ID: 37567825
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.
Bay P; de Chambrun MP; Rothstein V; Mahevas M; De Prost N; Roux A; Zuber B; Biet DI; Hervier B; Tazi A; Mouthon L; Mekinian A; Deligny C; Borie R; Meurice JC; Meyer A; Priou P; Savale L; De Saint Martin L; Gallay L; Cottin V; Blanchard E; Brillet PY; Khafagy P; Benveniste O; Nunes H; Allenbach Y; Uzunhan Y
J Autoimmun; 2022 Dec; 133():102941. PubMed ID: 36323067
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
19. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
20. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
Ge Y; Li S; Tian X; He L; Lu X; Wang G
Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
